Capecitabine CAS 154361-50-9 Raw Materials Powder

CAS: 154361-50-9

MF: C15H22FN3O6

MW: 359.35

EINECS: 604-948-1

Specification​: 99% min Capecitabine 

Sample: Capecitabine Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Capecitabine Powder Usage and Synthesis.

Capecitabine Powder (Capecitabine) is an antimetabolic fluoropyrimidine deoxynucleoside carbamate that can be converted to 5-FU in the body.

Capecitabine CAS 154361-50-9 inhibits cell division and interferes with RNA and protein synthesis. It is indicated for further treatment of advanced or metastatic breast cancer that has not responded to chemotherapy regimens including anthracyclines.

Capecitabine Raw Materials are primarily used for the treatment of advanced primary or metastatic breast, rectal, colon and gastric cancers.

Application/Function of Capecitabine Powder.

Capecitabine CAS 154361-50-9 is a new oral fluorinated pyrimidine drug that acts on tumor cells through a three-step enzyme chain reaction in vivo to convert to 5-FU. Its efficacy was significantly correlated with the level of TPase expression in tumor tissues and the expression of DPD enzymes in vivo. The high expression of TP in tumor tissues results in a differential drug gradient between tumor and normal tissues to achieve a relatively selective tumor-killing effect.

Animal experiments have shown that many drugs such as paclitaxel: paclitaxel, doxorubicin, mitomycin, and cisplatin can upregulate TPase expression in tumor tissues. Thus, they increase the anti-tumor effect of capecitabine, and these drugs themselves also have better efficacy in gastric cancer. When combined with capecitabine, there are both potentiation and synergistic effects.

Capecitabine Powder, as a convenient, safe and efficacious anti-cancer drug, has the potential to replace 5-FU as the basic drug in the combination chemotherapy regimen for gastric cancer.

It has been recommended by the National Institute for Health and Clinical Excellence (NICE) in the UK and the National Comprehensive Cancer Network (NCCN) in the US since its approval by the US FDA in 2001 and the European Medicines Agency (EMEA) in 2002 for use in metastatic breast cancer.

In China, Capecitabine has been approved for the treatment of metastatic breast cancer, adjuvant treatment of intestinal cancer and first-line treatment of metastatic intestinal cancer since its launch in 2001, until it was approved for the first-line treatment of advanced gastric cancer last year.

Capecitabine Powder is an anti-cancer drug mainly used for non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer and other solid tumors.

Capecitabine Tablets are mainly used for patients with malignant tumors and have a significant inhibitory effect on tumors, mainly by inhibiting cell division, thus acting as an inhibitor of tumors. Capecitabine is clinically used for colorectal cancer, gastric cancer, breast cancer, and other malignant tumors.

It should be noted that Capecitabine tablets may cause related side effects, i.e. common side effects of antineoplastic drugs, such as diarrhea, which in turn may lead to dehydration symptoms. It may also affect liver function and kidney function, resulting in abnormal blood-related indicators. During the use of Capecitabine tablets, strict contraceptive measures are required due to the teratogenic nature of the drug.

Capecitabine generally has the effect of inhibiting the progression of tumor cells. Capecitabine can inhibit the progression of tumor cells by inhibiting the replication of tumor cell DNA, mainly through competitive inhibitors. Among gastrointestinal malignancies, advanced breast cancer and lung cancer can achieve better efficacy, reduce the probability of recurrence and metastasis after surgery, and prolong the survival of patients with advanced disease. Capecitabine is usually used in combination with platinum-based chemotherapy drugs.